Tag: FLOW trial
Semaglutide reduces risk for major kidney disease events in patients with...
Findings from the FLOW trial, the first dedicated kidney outcomes trial with a glucagon-like peptide-1 (GLP-1) receptor agonist were reported at a symposium at...
Semaglutide significantly reduces risk of major kidney disease events and mortality...
A study recently published in the New England Journal of Medicine (NEJM) has demonstrated that semaglutide (Novo Nordisk) significantly reduces the risk of major...
FLOW trial shows reduction in kidney disease progression in patients with...
Novo Nordisk has announced via press release the headline results from the kidney outcomes trial FLOW, coming after the decision to stop the trial...